文献速递骨软组织肉瘤与黑色素瘤

真实世界队列研究:III期黑色素瘤术后辅助治疗的生存结局(TAMARIS)

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).
PubMed 文献 · Eur J Cancer · 2026-06-25

TAMARIS是一项法国多中心回顾性真实世界队列研究,纳入2018–2023年完全切除的III期黑色素瘤患者1016例,比较辅助治疗(抗PD-1或BRAFi/MEKi)与观察的总生存(OS)。辅助组OS显著优于对照组(HR 0.62,95%CI 0.47–0.80,P=0.003),IPTW校正后仍显著(HR 0.68,95%CI 0.49–0.94,P=0.020);但IIIA期亚组未见显著获益。

要点

  • III期黑色素瘤术后辅助治疗与OS改善相关(HR 0.62,95%CI 0.47–0.80)。
  • IPTW校正后OS获益仍显著(HR 0.68,95%CI 0.49–0.94,P=0.020)。
  • IIIA期患者辅助治疗未见显著OS获益。

核心结论

  • 真实世界数据显示III期黑色素瘤术后辅助治疗带来显著OS获益。
  • IIIA期疾病未见显著OS获益。

研究设计与样本

  • TAMARIS为法国多中心回顾性研究,基于RIC-Mel前瞻性真实世界数据库。
  • 纳入2018–2023年完全手术切除的AJCC第8版III期黑色素瘤患者1016例,中位年龄60岁。
  • 比较辅助治疗组与未接受系统治疗的对照组,采用Cox回归和IPTW校正偏倚。

主要发现

  • 701例(69%)接受辅助治疗:抗PD-1 588例,BRAFi/MEKi 113例。
  • 中位治疗持续时间10.9个月,中位随访29.6个月。
  • 辅助组OS显著优于对照组(HR 0.62,95%CI 0.47–0.80,P=0.003)。
  • 多因素分析和IPTW校正后OS获益仍显著(HR 0.68,95%CI 0.49–0.94,P=0.020)。
  • 多数亚组辅助治疗对OS有显著正向影响,但IIIA期除外。

关键数值与推荐

  • 辅助治疗对比观察的OS:HR 0.62(95%CI 0.47–0.80),P=0.003。
  • IPTW校正后OS:HR 0.68(95%CI 0.49–0.94),P=0.020。
  • IIIA期亚组辅助治疗未见显著OS获益。

临床怎么用

  • 支持III期黑色素瘤术后辅助治疗在真实世界中的OS获益。
  • IIIA期患者辅助治疗决策需个体化,因该亚组未见显著OS获益。

局限性

  • 回顾性真实世界研究,可能存在未测量混杂。
  • 已采用IPTW校正,但无法完全排除偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The approval of adjuvant treatment with anti-PD-1 antibodies (anti-PD-1) and BRAF and MEK inhibitors (BRAFi/MEKi) for resected stage III/IV melanoma was based on randomized controlled trials demonstrating a benefit in recurrence-free survival (RFS). However, none showed a significant impact on overall survival (OS). We aimed to evaluate the OS impact of adjuvant therapies in real-world settings. METHODS: TAMARIS is a national multicenter retrospective study evaluating the efficacy of anti-PD-1 and BRAFi/MEKi for resected stage III melanoma in a French real-life prospective database (RIC-Mel). Patients with resectable stage III melanoma (AJCC 8th edition), who underwent complete surgical resection between 2018 and 2023 were included. OS in patients who received an adjuvant treatment (adjuvant group) was compared to those who did not receive systemic therapies (control group). Associations between the adjuvant strategy (adjuvant treatment versus observation) and OS were evaluated using a Cox regression model and inverse probability treatment weighting (IPTW) in order to limit potential biases. Subgroup analyses by baseline characteristics and treatment regimens were also conducted. RESULTS: Among the 1016 patients (median age: 60 years) included, 701 (69%) received adjuvant therapies with either anti-PD-1 (n = 588) or BRAFi/MEKi (n = 113). The median treatment duration was 10.9 months, and the median follow-up was 29.6 months. OS was significantly higher in the adjuvant group compared to the control group (HR: 0.62, [IC95%, 0.47-0.80], P = 0.003) confirmed in multivariate analysis and after IPTW-adjustment (HR: 0.68, [IC95%, 0.49-0.94], P = 0.020). In subgroup analyses, adjuvant treatment had a significant positive impact on OS across most subgroups, but not for stage IIIA. CONCLUSION: These real-world data indicate a significant OS benefit of adjuvant therapy in patients with AJCC8 stage III melanoma, but not in those with stage IIIA disease.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Erard T, Quéreux G, Amini-Adle M, et al. Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS). Eur J Cancer. 2026. PMID: 42372635. doi:10.1016/j.ejca.2026.116878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。